Orphan disease biotech Versartis files for a $80 million IPO

Comment

Shutterstock photo

Versartis, a biotech developing long-acting treatments for growth hormone deficiency, filed on Tuesday with the SEC to raise up to $80 million in an initial public offering. The Redwood City, CA-based company was founded in 2008. Versartis initially filed confidentially on January 10, 2014. Morgan Stanley and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com